As usual, the 2016 Annual Meeting of the American Society of Hematology (ASH) has raised a lot of excitement in the Hematology community. Immunotherapy is again one of the hottest topics and Naveen Pemmaraju, MD from the University of Texas MD Anderson, Houston, TX refers to it as one of the main subjects to look out for at this meeting. This year we learn more about the efficacy and benefits of these treatments, as well as the side effects and toxicities associated with them. One of the main focus of the healthcare community in past years is to reduce the dosage of chemotherapy while maintaining its efficacy. Topics such as this and treatment discontinuation, are also one of the highlights for Dr Naveen. Last, but not least, are the JAK inhibitors’ data in myeloproliferative neoplasms that will be presented at the meeting. This includes not only FDA-approved drug ruxolitinib, but also the novel agents pacritinib and momelotinib.
